보도 자료는 일본의 FUJIFILM Corporation에서 발행합니다.
보도 자료에 있는 제품들은 국가및 지역에 따라 이용 가능 여부가 상이합니다.
본 웹사이트의 콘텐츠는 발표일 현재의 내용이며 사전 통지 없이 변경될 수 있습니다. 제품 가용성, 사양, 가격, 연락처 등 각 보도 자료에 포함된 정보는 게시 시점 기준 정보입니다.
- Jun 2, 2025
- Fujifilm Rebrands Life Sciences Companies to Strengthen Position as Strategic Partners for Life, Offering End-to-End Solutions
- Apr 22, 2025
- FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-year U.S. Manufacturing Agreement Valued at Over $3 Billion
- Nov 5, 2024
- FUJIFILM Diosynth Biotechnologies Launches First Phase of Global CDMO Ecosystem Expansion
- Apr 12, 2024
- Fujifilm to Invest Additional $1.2 Billion to Expand its Large-Scale Cell Culture CDMO Business in North Carolina
- Feb 29, 2024
- FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA with Better Energy for Denmark Manufacturing Site
- Dec 5, 2023
- Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities
- Nov 8, 2023
- FUJIFILM Diosynth Biotechnologies Announces First Tenant for New Manufacturing Facility
- Jun 6, 2023
- Fujifilm to Enhance Commercial Presence in Asia for Biologics and Advanced Therapies Contract Services
- Mar 31, 2023
- Transfer of FUJIFILM Healthcare Systems’ electronic medical record and medical-receipt systems related business to PHC Holdings’ subsidiary
- Dec 20, 2022
- Fujifilm Announces Asset Purchase Agreement with Inspirata, Inc. to acquire the company’s Digital Pathology Business
- Dec 14, 2022
- Fujifilm Invests in PhenoVista Biosciences from its Life Sciences Corporate Venture Capital Fund
- Oct 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan